Clinical trial
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
NCT00130897 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
- Lead sponsor
- Pfizer
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- July 31, 2005
- Completion date
- November 30, 2011
- Enrollment
- Not reported
- Sites
- 271
Conditions
As the registry lists them; a condition with its own page is linked.